Travere Therapeutics, Inc. (TVTX)

NASDAQ: TVTX · IEX Real-Time Price · USD
8.65
+0.84 (10.76%)
At close: Dec 7, 2023, 4:00 PM
8.98
+0.33 (3.82%)
After-hours: Dec 7, 2023, 5:46 PM EST
10.76%
Market Cap 586.89M
Revenue (ttm) 209.65M
Net Income (ttm) -87.05M
Shares Out 75.15M
EPS (ttm) -1.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,096,350
Open 7.84
Previous Close 7.81
Day's Range 7.82 - 8.77
52-Week Range 5.25 - 23.18
Beta 0.53
Analysts Buy
Price Target 20.57 (+137.8%)
Earnings Date Nov 7, 2023

About TVTX

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola a... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Eric M. Dube Ph.D.
Employees 462
Stock Exchange NASDAQ
Ticker Symbol TVTX
Full Company Profile

Financial Performance

In 2022, TVTX's revenue was $212.02 million, a decrease of -6.80% compared to the previous year's $227.49 million. Losses were -$278.48 million, 54.6% more than in 2021.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for TVTX stock is "Buy." The 12-month stock price forecast is $20.57, which is an increase of 137.80% from the latest price.

Price Target
$20.57
(137.80% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference

SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on Tues...

16 days ago - GlobeNewsWire

Travere Therapeutics Reports Third Quarter 2023 Financial Results

Received 430 new patient start forms for FILSPARI ®  (sparsentan) in the third quarter of 2023; demand and payer coverage continued to grow

4 weeks ago - GlobeNewsWire

Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023

“The totality of data from the PROTECT study demonstrates FILSPARI is effective, safe and has an important place in the IgAN treatment landscape

4 weeks ago - GlobeNewsWire

Travere Therapeutics to Report Third Quarter 2023 Financial Results

SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2023 financial results on Tuesday, November 7, 2023, after the close...

6 weeks ago - GlobeNewsWire

Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI ® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS

7 weeks ago - GlobeNewsWire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on October 10, 2023, the Compensation Committee of its Board of Directors granted inducement...

2 months ago - GlobeNewsWire

Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)

SAN DIEGO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present preliminary findings from the SPARTAN Study ...

2 months ago - GlobeNewsWire

Travere Therapeutics shares plunge as kidney-disease treatment has mixed results in trial

Travere Therapeutics Inc. shares TVTX dropped 37% premarket on Thursday after the company released data from a late-stage study of Filspari in IgA nephropathy, a rare kidney disease. In a head-to-head...

2 months ago - Market Watch

Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan

SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced topline two-year confirmatory secondary endpoint results from the Company's pivotal head-to-head...

2 months ago - GlobeNewsWire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on September 10, 2023, the Compensation Committee of its Board of Directors granted inducem...

3 months ago - GlobeNewsWire

Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals

• Travere received $210 million at closing and is eligible for up to $235 million in potential sales-based milestone payments • Mirum has acquired Travere's rights and assets related to Cholbam ® and ...

3 months ago - GlobeNewsWire

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics

FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Thera...

Other symbols: MIRM
3 months ago - Business Wire

Travere Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference

SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 2023 Wells Fargo Healthcare Conference on Thursday, S...

3 months ago - GlobeNewsWire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 25, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therape...

3 months ago - Accesswire

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

SAN DIEGO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company will present clinical data from the Phase 1/2 COMPOSE Study of pegtibatinase, a ...

3 months ago - GlobeNewsWire

Travere Therapeutics Reports Second Quarter 2023 Financial Results

•   Received 417 new patient start forms for FILSPARI™(sparsentan) in the second quarter 2023, reflecting continued strong demand from nephrologists and patients with IgA nephropathy (IgAN)

4 months ago - GlobeNewsWire

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / August 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeu...

4 months ago - Accesswire

Biotech stock Travere Therapeutics is trading at a deep discount: JPMorgan

Travere Therapeutics Inc (NASDAQ: TVTX) has been a disappointment for shareholders since early May but a JPMorgan analyst expects it to recover over the next 18 months. Travere Therapeutics shares hav...

4 months ago - Invezz

Travere Therapeutics to Report Second Quarter 2023 Financial Results

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2023 financial results on Thursday, August 3, 2023, after the close...

5 months ago - GlobeNewsWire

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics

FOSTER CITY, Calif. & SAN DIEGO--(BUSINESS WIRE)-- #liverdisease--Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Th...

Other symbols: MIRM
5 months ago - Business Wire

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 7, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeuti...

5 months ago - Accesswire

INVESTIGATION ALERT: The Gross Law Firm Notifies Shareholders of Travere Therapeutics, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ: TVTX)

NEW YORK , July 6, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Travere Therapeutics, Inc.: The investigation focuses on whether Travere issued false and/or m...

5 months ago - PRNewsWire

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 4, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeuti...

5 months ago - Accesswire

TVTX ALERT: The Law Offices of Vincent Wong Investigate Travere Therapeutics, Inc. for Potential Violations of Securities Laws

NEW YORK , July 3, 2023 /PRNewswire/ -- Attention Travere Therapeutics, Inc. ("Travere") (NASDAQ: TVTX) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into ...

5 months ago - PRNewsWire

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Travere Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Travere Therapeuti...

5 months ago - Accesswire